Taysha Gene Therapies Stock Current Liabilities
| TSHA Stock | USD 2.40 0.12 4.76% |
Taysha Gene Therapies fundamentals help investors to digest information that contributes to Taysha Gene's financial success or failures. It also enables traders to predict the movement of Taysha Stock. The fundamental analysis module provides a way to measure Taysha Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taysha Gene stock.
The current year's Non Current Liabilities Other is expected to grow to about 2.7 M, whereas Total Current Liabilities is forecasted to decline to about 34.9 M. Taysha | Current Liabilities |
Taysha Gene Therapies Company Current Liabilities Analysis
Taysha Gene's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Taysha Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Taysha Gene is extremely important. It helps to project a fair market value of Taysha Stock properly, considering its historical fundamentals such as Current Liabilities. Since Taysha Gene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Taysha Gene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Taysha Gene's interrelated accounts and indicators.
Click cells to compare fundamentals
Taysha Current Liabilities Historical Pattern
Today, most investors in Taysha Gene Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Taysha Gene's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Taysha Gene current liabilities as a starting point in their analysis.
Taysha Gene Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Taysha Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Taysha Gene Therapies has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Taysha Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taysha Gene's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taysha Gene could also be used in its relative valuation, which is a method of valuing Taysha Gene by comparing valuation metrics of similar companies.Taysha Gene is currently under evaluation in current liabilities category among its peers.
Taysha Gene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Taysha Gene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Taysha Gene's managers, analysts, and investors.Environmental | Governance | Social |
Taysha Fundamentals
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (11.78) % | ||||
| Current Valuation | 429.5 M | ||||
| Shares Outstanding | 204.94 M | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 77.19 % | ||||
| Number Of Shares Shorted | 15.75 M | ||||
| Price To Book | 5.82 X | ||||
| Price To Sales | 52.92 X | ||||
| Revenue | 15.45 M | ||||
| Gross Profit | 2.5 M | ||||
| EBITDA | (105.2 M) | ||||
| Net Income | (111.57 M) | ||||
| Cash And Equivalents | 66.24 M | ||||
| Cash Per Share | 1.61 X | ||||
| Total Debt | 61.11 M | ||||
| Debt To Equity | 1.93 % | ||||
| Current Ratio | 1.79 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (73.02 M) | ||||
| Short Ratio | 2.13 X | ||||
| Earnings Per Share | 0.63 X | ||||
| Target Price | 6.59 | ||||
| Number Of Employees | 52 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 524.65 M | ||||
| Total Asset | 172.73 M | ||||
| Retained Earnings | (513.01 M) | ||||
| Working Capital | 113.11 M | ||||
| Net Asset | 172.73 M |
About Taysha Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taysha Gene Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taysha Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taysha Gene Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Taysha Gene Therapies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taysha Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taysha Gene Therapies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taysha Gene Therapies Stock:Check out Taysha Gene Piotroski F Score and Taysha Gene Altman Z Score analysis. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.